FOLH1 and prostate cancer: The growing use of target‐specific PET tracers (e.g., 18F‐PSMA‐1007 and 68Ga‐PSMA in prostate cancer, 18F‐FES in breast cancer) allows the development of further algorithms predicting histologic diagnosis and molecular tumour classification [105, 106, 107, 108, 109].